Viking Therapeutics Skyrockets On Obesity Drug Data. Eli Lilly, Novo Fall.
Viking Therapeutics shares rose up to 36% following positive topline results from a maintenance study of its GLP-1/GIP agonist, VK2735. The drug demonstrated strong weight-loss retention with once-a-month dosing regimens. Market reaction saw Viking stock skyrocket while competitors Eli Lilly and Novo Nordisk declined. One report indicates the treatment achieved 22% more weight loss than a placebo by week 33 without reaching a plateau. Recent trading data shows the stock holding above a key support level of $32.11 despite a minor slip of 1.86%.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ Viking Therapeutics stock surged up to 36% following weight-loss drug trial data.
- ✓ The maintenance study for GLP-1/GIP agonist VK2735 showed positive topline results.
- ✓ VK2735 demonstrates weight-loss retention using monthly dosing.
- ✓ Shares of Eli Lilly and Novo Nordisk fell as Viking Therapeutics stock rose.
What changed
Viking Therapeutics released topline maintenance study results for its obesity drug VK2735 showing efficacy with monthly dosing.
Live updates
-
Viking Therapeutics Stock Surges on VK2735 Weight-Loss Maintenance Data
Viking Therapeutics shares rose up to 36% following positive topline results from a maintenance study of its GLP-1/GIP agonist, VK2735. The drug demonstrated strong weight-loss retention with once-a-month dosing regimens. Market reaction saw Viking stock skyrocket while competitors Eli Lilly and Novo Nordisk declined. One report indicates the treatment achieved 22% more weight loss than a placebo by week 33 without reaching a plateau. Recent trading data shows the stock holding above a key support level of $32.11 despite a minor slip of 1.86%.
Why it matters
VK2735 competes in the high-growth obesity market against established GLP-1 therapies. The ability to maintain weight loss with monthly dosing could reduce patient burden and increase competitiveness. This data tests the long-term efficacy of Viking's candidate compared to existing industry leaders.
What is confirmed
- Viking Therapeutics stock surged up to 36% following weight-loss drug trial data.
- The maintenance study for GLP-1/GIP agonist VK2735 showed positive topline results.
- VK2735 demonstrates weight-loss retention using monthly dosing.
- Shares of Eli Lilly and Novo Nordisk fell as Viking Therapeutics stock rose.
Still unconfirmed
- The weight-loss treatment showed 22% more loss than a placebo by week 33 with no plateau.
- Viking Therapeutics stock slipped 1.86% while holding above a key support level of $32.11.
What to watch next
- Full peer-reviewed data release from the VK2735 maintenance study
- Regulatory filing updates for the VK2735 clinical pipeline
- Comparative efficacy trials against Eli Lilly and Novo Nordisk products
confidence 90%Sources used for this update (9)
- Investor's Business Daily — Viking Therapeutics Skyrockets On Obesity Drug Data. Eli Lilly, Novo Fall.
- Seeking Alpha — Viking Therapeutics stock soars on obesity data (VKTX:NASDAQ)
- Barron's — Viking Therapeutics Stock Surges 36% After Weight-Loss Drug Trial
- careplusvn.com — Viking Therapeutics (VKTX) Slips 1.86% as Stock Holds Above Key Support at $32.11 - Trend Following Picks
- Stock Titan — A weight-loss treatment showed 22% more loss than a placebo by week 33. No plateau was seen.
- Yahoo Finance — Viking Therapeutics’ VK2735 Shows Strong Weight-Loss Retention With Monthly Dosing
- PR Newswire — Viking Therapeutics Announces Positive Topline Results from Maintenance Study of GLP-1/GIP Agonist VK2735 Demonstrating the Promise of Multiple Maintenance Dosing Regimens
- Yahoo Finance — Viking shares surge on updated obesity drug data
- endpoints.news — Viking touts once-a-month maintenance data for its weight loss candidate
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community